

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2<sup>nd</sup> Floor, Pushpawati Building No. 2, Girgaon Road, Chandanwadi, Mumbai -02

Corp. Off. : "Suryarath", 1<sup>st</sup> Floor, Panchwati, 1<sup>st</sup> Lane, Ambawadi, Ahmedabad - 06

Phone: +91-6359637788, Email: [investor\\_relations@jindalonline.com](mailto:investor_relations@jindalonline.com),

Website: [www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com)

Date: 9<sup>th</sup> February, 2019

To,  
BSE Limited  
Listing Department  
Phiroz Jeejeebhoy Tower,  
25<sup>th</sup> Floor, Dalal Street,  
Mumbai-400 001

Scrip Code - 531960

Sub.: Outcome of Board Meeting held on 9<sup>th</sup> February, 2019 as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to above and as per intimation given for meeting of the Board of Directors, we are pleased to inform that above referred meeting was held on 9<sup>th</sup> February, 2019 and Board of Directors has considered and approved, inter alia:

1. the Unaudited Financial Results of the Company for the third quarter and nine months ended 31<sup>st</sup> December, 2018 as per Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; and
2. all other businesses as per agenda circulated.


The Meeting of the Board of Directors commenced at 12.30 p.m. and concluded at 1.00 p.m.

Kindly take the above disclosures on your record as compliance with Regulations 30 and 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

You are requested to take note of the same.

Thanking you.

Yours faithfully,  
For, Kashyap Tele-Medicines Limited

  
Prerna Kakkar  
Company Secretary



Encl: As above



# SAREMAL & CO

## Chartered Accountants

CA Saremal shah (Bcom, FCA); CA Pravin Lavana (Bcom, LLB, FCA)

### LIMITED REVIEW REPORT

To  
The Board of Directors,  
**KASHYAP TELE-MEDICINES LIMITED**  
**AHMEDABAD**

1. We have reviewed the accompanying statement of Un-audited Financial Results of **M/S KASHYAP TELE-MEDICINES LIMITED** (the Company) for the third quarter and nine months ended 31<sup>st</sup> December, 2018 being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015 read with Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Statement on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by Independent Auditor of the Entity" & (SRE) 2400 "Engagements to Review Financial Statements", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review consist of making inquiries, primarily of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 with Circular No. CIR/CFD/FAC/62/2016 dated 5<sup>th</sup> July, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place : Ahmedabad  
Date: 9<sup>th</sup> February, 2019



FOR, SAREMAL & CO.  
CHARTERED ACCOUNTANTS

  
PRAVIN LAVANA  
(PARTNER)  
MEMBERSHIP NO.: 037180  
FIRM REGISTRATION NO.: 109281W

# KASHYAP TELE-MEDICINES LIMITED

CIN: L29110MH1995PLC085738

Regd. Off.: 2nd Floor, Pushpawati Building No. 2, Girgaon Road, Chandaonwadi, Mumbai -02

Corp. Off. : "Suryarath", 1st Floor, Panchwati, 1st Lane, Ambawadi, Ahmedabad - 06

Phone: +91-6359637788, Email: investor.relations@jindalonline.com

Website: www.kashyaptele-medicines.com

## STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2018

(Rs in Lacs Except EPS)

Sr.No.	Particulars	Quarter Ended (Standalone)			Nine Months Ended		Year Ended
		31/12/2018	30/09/2018	31/12/2017	31/12/2018	31/12/2017	31/03/2018
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
I	Revenue from operations	4.65	4.65	4.65	13.95	13.35	18.00
II	Other Income	0.00	0.00	0.00	0.00	0.04	0.11
III	<b>Total Revenue ( I + II )</b>	<b>4.65</b>	<b>4.65</b>	<b>4.65</b>	<b>13.95</b>	<b>13.39</b>	<b>18.11</b>
IV	<b>Expenses</b>						
	(a) Cost of materials consumed	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Purchases of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
	(d) Employee benefits expense	2.18	1.95	1.91	5.96	4.65	6.27
	(e) Finance Cost	0.00	0.00	0.00	0.00	0.00	0.00
	(f) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00	0.00
	(g) Other expenses	1.42	2.32	1.80	4.96	5.08	6.91
	<b>Total Expenses</b>	<b>3.60</b>	<b>4.27</b>	<b>3.71</b>	<b>10.92</b>	<b>9.73</b>	<b>13.18</b>
V	<b>Profit/(Loss) before exceptional and extraordinary items and tax (III-IV)</b>	<b>1.05</b>	<b>0.38</b>	<b>0.94</b>	<b>3.03</b>	<b>3.66</b>	<b>4.93</b>
VI	Exceptional and Extraordinary Items	0.00	0.00	0.00	0.00	0.00	0.00
VII	<b>Profit/(Loss) Before Tax ( V- VI)</b>	<b>1.05</b>	<b>0.38</b>	<b>0.94</b>	<b>3.03</b>	<b>3.66</b>	<b>4.93</b>
VIII	Tax Expense :-						
	(a) Current Tax	0.28	0.08	0.24	0.77	0.94	0.94
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	0.00
	<b>Total Tax Expense</b>	<b>0.28</b>	<b>0.08</b>	<b>0.24</b>	<b>0.77</b>	<b>0.94</b>	<b>0.94</b>
IX	<b>Profit / (Loss) for the period from Continuing Operations (VII-VIII)</b>	<b>0.77</b>	<b>0.30</b>	<b>0.70</b>	<b>2.26</b>	<b>2.72</b>	<b>3.99</b>
X	Profit/(Loss) from Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XI	Tax expense of Discontinuing Operations	0.00	0.00	0.00	0.00	0.00	0.00
XII	Profit/(Loss) from Discontinuing Operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00
XIII	<b>Profit / (Loss) for the period ( IX + XII )</b>	<b>0.77</b>	<b>0.30</b>	<b>0.70</b>	<b>2.26</b>	<b>2.72</b>	<b>3.99</b>
XIV	Share of Profit / (Loss) of Associates	N.A	N.A	N.A	N.A	N.A	N.A
XV	Minority interest	N.A	N.A	N.A	N.A	N.A	N.A
XVI	<b>Net Profit / (Loss) after taxes</b>	<b>0.77</b>	<b>0.30</b>	<b>0.70</b>	<b>2.26</b>	<b>2.72</b>	<b>3.99</b>
XVII	<b>Other Comprehensive Income</b>						
	A. Items that will be/will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
	B. Income tax relating to items that will be / will not be reclassified to profit and loss	0.00	0.00	0.00	0.00	0.00	0.00
XVIII	<b>Total comprehensive income for the period (XVI+XVII)</b>	<b>0.77</b>	<b>0.30</b>	<b>0.70</b>	<b>2.26</b>	<b>2.72</b>	<b>3.99</b>
XIX	<b>Paid-up Equity Share Capital (Face Value of Rs. 1/- each)</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>	<b>477.22</b>
XX	<b>Reserve excluding Revaluation Reserves as per Balance Sheet as at previous financial year ended 31st March, 2018</b>						254.51
XXI	<b>Earnings per equity Share: (not annualised)</b>	<b>0.002</b>	<b>0.001</b>	<b>0.001</b>	<b>0.005</b>	<b>0.006</b>	<b>0.008</b>
	<b>(a) Basic and Diluted EPS (XVI/XIX)</b>						

**Notes:-**

- 1 The above Unaudited Financial Results of the Company for the third quarter and nine months ended 31st December, 2018 have been reviewed by the Audit Committee and approved by the Board of Directors in their Meetings held on 9th February, 2019.
- 2 The Company has adopted, Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ('Ind AS') from 1st April, 2017 and accordingly these financial results and all the periods presented have been prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 "Interim Financial Reporting" read with relevant rules issued thereunder and the other accounting principles generally accepted in India and discloses the information required to be disclosed in terms of Regulation 33 of the SEBI ( Listing Obligations and Disclosure Requirements) Regulation, 2015 (as amended).
- 3 The Statutory Auditors of the Company have carried out Limited Review of the above Unaudited Financial Results for the third quarter and nine months ended 31st December, 2018 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.
- 4 A Copy of the aforesaid financial results is also available on the website of BSE Limited ([www.bseindia.com](http://www.bseindia.com)) and on the website of the Company ([www.kashyaptele-medicines.com](http://www.kashyaptele-medicines.com)).
- 5 The Company is engaged in single segment therefore has only one reportable segment in accordance with Ind AS 108 'operating segments'.
- 6 Figures pertaining to previous year/periods have been re-grouped and re-arranged wherever necessary.

Place : Ahmedabad

Date : 9th February, 2019



For, Kashyap Tele - Medicines Limited



Amit Agrawal  
Managing Director  
DIN: 00169061